For patients in the secondary AML subgroup, ≥ 5 mutations were reported in three genes in the glasdegib + LDAC arm (DNMT3A, RUNX1, and TET2) and one gene in the LDAC alone arm (TET2). This evidence concerns the gene DNMT3A and acute myeloid leukemia.